| Q35109579 | A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity. |
| Q41928187 | A large-scale, multi-center serum metabolite biomarkers identification study for the early detection of hepatocellular carcinoma. |
| Q92076849 | AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease |
| Q64261592 | Acarbose improves health and lifespan in aging HET3 mice |
| Q90307736 | An Untargeted Metabolomics Approach to Investigate the Metabolic Effect of Beetroot Juice Supplementation in Fencers-A Preliminary Study |
| Q35965157 | Associations between maternal lipid profile and pregnancy complications and perinatal outcomes: a population-based study from China |
| Q41996948 | BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis |
| Q36607910 | Bile Acid Receptors and Liver Cancer |
| Q43620015 | Bile acid TUDCA improves insulin clearance by increasing the expression of insulin-degrading enzyme in the liver of obese mice |
| Q38364542 | Bile acid activated receptors are targets for regulation of integrity of gastrointestinal mucosa |
| Q28085493 | Bile acid nuclear receptor FXR and digestive system diseases |
| Q36796803 | Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. |
| Q35976675 | Bile acids acutely stimulate insulin secretion of mouse β-cells via farnesoid X receptor activation and K(ATP) channel inhibition |
| Q53192870 | Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway. |
| Q35703158 | Bile diversion to the distal small intestine has comparable metabolic benefits to bariatric surgery. |
| Q57114151 | Bile diversion, a bariatric surgery, and bile acid signaling reduce central cocaine reward |
| Q61829990 | Biological processes and signal transduction pathways regulated by the protein methyltransferase SETD7 and their significance in cancer |
| Q53065775 | Bone Marrow Cell Transplant From Donors With Cardiovascular Risk Factors Increases the Pro-atherosclerotic Phenotype in the Recipients. |
| Q93092528 | Bridging intestinal immunity and gut microbiota by metabolites |
| Q37004159 | C/EBPβ in bone marrow is essential for diet induced inflammation, cholesterol balance, and atherosclerosis |
| Q50962482 | Cholestyramine alters bile acid amounts and the expression of cholesterol-related genes in rabbit intestinal and hepatic tissues. |
| Q64917645 | Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH. |
| Q33578547 | Commensal bacteria at the interface of host metabolism and the immune system |
| Q38186099 | Critical review of non-statin treatments for dyslipoproteinemia. |
| Q38986670 | Decoding the vasoregulatory activities of bile acid-activated receptors in systemic and portal circulation: role of gaseous mediators |
| Q39005761 | Design, Synthesis, and Biological Evaluation of Novel Nonsteroidal Farnesoid X Receptor (FXR) Antagonists: Molecular Basis of FXR Antagonism. |
| Q92461347 | Detection of Secondary Metabolites as Biomarkers for the Early Diagnosis and Prevention of Type 2 Diabetes |
| Q34729209 | Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery |
| Q28114796 | Diacylglycerol kinase θ couples farnesoid X receptor-dependent bile acid signalling to Akt activation and glucose homoeostasis in hepatocytes |
| Q37699321 | Digestive physiology of the pig symposium: intestinal bile acid sensing is linked to key endocrine and metabolic signaling pathways |
| Q64121752 | Discovery of ((1,2,4-oxadiazol-5-yl)pyrrolidin-3-yl)ureidyl derivatives as selective non-steroidal agonists of the G-protein coupled bile acid receptor-1 |
| Q27309876 | Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis |
| Q35208562 | Effect of Roux-en-Y gastric bypass surgery on bile acid metabolism in normal and obese diabetic rats |
| Q36293600 | Effect of tight glucose control with insulin on the thyroid axis of critically ill children and its relation with outcome |
| Q48247400 | Effects of Bariatric Surgery on Serum Bile Acid Composition and Conjugation in a Diabetic Rat Model. |
| Q48140222 | Effects of Sleeve Gastrectomy on Serum 12α-Hydroxylated Bile Acids in a Diabetic Rat Model. |
| Q34168512 | Effects of deoxycholylglycine, a conjugated secondary bile acid, on myogenic tone and agonist-induced contraction in rat resistance arteries |
| Q51265948 | Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial. |
| Q39390970 | Endocrine Function after Bariatric Surgery |
| Q57123300 | Enterobacteria Modulate Intestinal Bile Acid Transport and Homeostasis through Apical Sodium-Dependent Bile Acid Transporter (SLC10A2) Expression |
| Q38009566 | Epigenomic regulation of bile acid metabolism: emerging role of transcriptional cofactors |
| Q58861672 | Epoxide functionalization on cholane side chains in the identification of G-protein coupled bile acid receptor (GPBAR1) selective agonists |
| Q38548688 | Farnesoid X receptor modulators (2011 - 2014): a patent review |
| Q90136397 | Fecal medicines used in traditional medical system of China: a systematic review of their names, original species, traditional uses, and modern investigations |
| Q90012752 | Free fatty acid receptors, G protein-coupled receptor 120 and G protein-coupled receptor 40, are essential for oil-induced gastric inhibitory polypeptide secretion |
| Q98952094 | Gut microbiota in human metabolic health and disease |
| Q35733648 | Gut permeability, its interaction with gut microflora and effects on metabolic health are mediated by the lymphatics system, liver and bile acid. |
| Q37590250 | HDL and cholesterol: life after the divorce? |
| Q90296417 | Hepatic Autophagy Deficiency Compromises Farnesoid X Receptor Functionality and Causes Cholestatic Injury |
| Q37707412 | High-density lipoproteins and cardiovascular disease: 2010 update |
| Q64940064 | Human-specific dual regulations of FXR-activation for reduction of fatty liver using in vitro cell culture model. |
| Q38291812 | IFN-γ secretion in gut of Ob/Ob mice after vertical sleeve gastrectomy and its function in weight loss mechanism |
| Q38897837 | Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening |
| Q35819570 | Impact of Gut Microbiota on Obesity, Diabetes, and Cardiovascular Disease Risk |
| Q35855133 | Impaired Itching Perception in Murine Models of Cholestasis Is Supported by Dysregulation of GPBAR1 Signaling |
| Q28070321 | Improved glucose metabolism following bariatric surgery is associated with increased circulating bile acid concentrations and remodeling of the gut microbiome |
| Q55226284 | In Vitro Modeling of Bile Acid Processing by the Human Fecal Microbiota. |
| Q26752511 | Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1 |
| Q43102009 | Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists. |
| Q37206952 | Insulin Resistance is Associated With Total Bile Acid Level in Type 2 Diabetic and Nondiabetic Population: A Cross-Sectional Study |
| Q37429742 | Intercellular Lipid Mediators and GPCR Drug Discovery |
| Q35904758 | Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children |
| Q35234322 | Intrafollicular cortisol levels inversely correlate with cumulus cell lipid content as a possible energy source during oocyte meiotic resumption in women undergoing ovarian stimulation for in vitro fertilization |
| Q64084645 | Introduction of Nonacidic Side Chains on 6-Ethylcholane Scaffolds in the Identification of Potent Bile Acid Receptor Agonists with Improved Pharmacokinetic Properties |
| Q82486866 | Long distance calling for liver regeneration: Identification of neuroendocrine signalling pathways activated after partial hepatectomy |
| Q26770832 | Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors |
| Q49394966 | Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis |
| Q97643856 | Microbial regulation of organismal energy homeostasis |
| Q42672574 | Molecular characterization, tissue expression profile and SNP analysis of the porcine NR1H4 gene |
| Q28831219 | Navigation in bile acid chemical space: discovery of novel FXR and GPBAR1 ligands |
| Q60934128 | Overview of Bile Acids Signaling and Perspective on the Signal of Ursodeoxycholic Acid, the Most Hydrophilic Bile Acid, in the Heart |
| Q34901544 | Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice |
| Q60047622 | Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome |
| Q51717906 | Pharmacophore modeling, comprehensive 3D-QSAR, and binding mode analysis of TGR5 agonists. |
| Q34054283 | Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation |
| Q43503691 | Positive regulation of osteogenesis by bile acid through FXR. |
| Q42518451 | Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients |
| Q48177243 | Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics. |
| Q36972583 | Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor |
| Q44964426 | Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers |
| Q34694229 | Regulation of FXR transcriptional activity in health and disease: Emerging roles of FXR cofactors and post-translational modifications |
| Q57108067 | Rethinking Bile Acid Metabolism and Signaling for Type 2 Diabetes Treatment |
| Q35833255 | Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H2S Generation and Endothelin-1. |
| Q92269205 | Role for diet in normal gut barrier function: developing guidance within the framework of food-labeling regulations |
| Q36497654 | Role of nuclear receptors in lipid dysfunction and obesity-related diseases. |
| Q39600541 | SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-γ by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts |
| Q47238539 | Small Intestinal Bypass Induces a Persistent Weight-Loss Effect and Improves Glucose Tolerance in Obese Rats |
| Q38541491 | Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application |
| Q41022676 | Structure based classification for bile salt export pump (BSEP) inhibitors using comparative structural modeling of human BSEP. |
| Q43175647 | Structure-based drug design targeting the cell membrane receptor GPBAR1: exploiting the bile acid scaffold towards selective agonism |
| Q34955918 | Studies in mice, hamsters, and rats demonstrate that repression of hepatic apoA-I expression by taurocholic acid in mice is not mediated by the farnesoid-X-receptor |
| Q42140794 | Studying the Differences of Bacterial Metabolome and Microbiome in the Colon between Landrace and Meihua Piglets |
| Q36290513 | Synthesis and biological evaluations of chalcones, flavones and chromenes as farnesoid x receptor (FXR) antagonists |
| Q44134783 | Synthesis and quantitative structure-property relationships of side chain-modified hyodeoxycholic acid derivatives. |
| Q36790557 | TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn's disease |
| Q35094206 | TGR5: a novel target for weight maintenance and glucose metabolism |
| Q37727582 | Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases |
| Q26738730 | Targeting the gastrointestinal tract to treat type 2 diabetes |
| Q38700513 | The Bile Acid Receptor GPBAR1 Regulates the M1/M2 Phenotype of Intestinal Macrophages and Activation of GPBAR1 Rescues Mice from Murine Colitis. |
| Q30486707 | The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors |
| Q35249092 | The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ light-chain enhancer of activated B cells (NF-κB) in mice |
| Q38115636 | The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders. |
| Q28590901 | The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis |
| Q37641553 | The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines. |
| Q22122073 | The genome of the hydatid tapeworm Echinococcus granulosus |
| Q24314242 | The nuclear receptor FXR regulates hepatic transport and metabolism of glutamine and glutamate |
| Q57107473 | The role of bile acids in nutritional support |
| Q64911067 | Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation. |
| Q92464070 | Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents |
| Q36494764 | Unifying mechanisms of action of the anticancer activities of triterpenoids and synthetic analogs |
| Q43125212 | Utility of the carboxylesterase inhibitor bis-para-nitrophenylphosphate (BNPP) in the plasma unbound fraction determination for a hydrolytically unstable amide derivative and agonist of the TGR5 receptor |